On February 28, 2025, the FDA quietly did something that should have made headlines in every firehouse in America: it removed the cardiovascular black box warning from all testosterone replacement therapy products. The warning that had shaped how doctors prescribed TRT — and how patients feared it — for over a decade was gone. Wiped based on evidence.
Then, in December 2025, an FDA expert panel went further. Thirteen clinicians, urologists, and federal health officials convened and called for TRT to be descheduled from its Schedule III controlled substance classification entirely — the same category as anabolic steroids — and for approved indications to be expanded. FDA Commissioner Martin Makary opened the session with a question that cut straight through a decade of institutional hedging:
"According to the Journal of Clinical Endocrinology and Metabolism, 5.6% of men aged 30 to 79 have low testosterone and symptoms. Why are we ignoring this topic?"
One panelist, Dr. Helen Bernie, a urologist at Indiana University, was more direct:
"We are failing men. If we want to improve the health of American men, if we want to close the mortality gap, we must recognize testosterone deficiency for what it is: a public health issue."
Another panelist put it plainly:
"Testosterone is still regulated as if it were a dangerous, performance-enhancing drug from the athletic doping scandals of the 1980s. And because of this outdated classification, many physicians fear prescribing it or even screening for it."
The guidance circulating in fire departments right now — the union health trust posts, the physician-authored info documents — was written before any of this. Some of it was written in 2020. The science has moved. The regulatory consensus has moved. The institutional messaging hasn't.
Firefighters Don't Have a Lifestyle Problem. They Have an Occupational One.
The standard playbook for low T advice goes like this: lose weight, sleep more, eat better, stress less, and then maybe consider TRT if levels are still low after all that.
That advice was written for someone else's physiology and someone else's schedule.
A study of 72 firefighters with an average age of 25 — not middle-aged men, not overweight men — showed T levels drop from an average of 732 ng/dL down to 464 ng/dL over just their first year on the job. Not gradually over a career. Year one. Sleep deprivation alone can reduce testosterone by 10% after a single week of poor sleep — the equivalent of a decade of normal aging. Extreme physical exertion without adequate recovery suppresses T. Chronic occupational stress suppresses T. These aren't lifestyle choices. They're the job description.
A 2024 study of 341 Florida career firefighters found that lower testosterone was directly associated with reduced physical fitness measures during occupational health evaluations — not just energy and libido, but the physical capabilities assessed to determine whether someone is fit for duty.
When the advice is "try lifestyle changes first," it assumes the low T is caused by choices. For firefighters, it's more often caused by the work itself.
What Low T Actually Costs in the Field
Physical readiness
Testosterone regulates muscle mass, strength, and recovery. A firefighter with chronically suppressed T is recovering slower between shifts, losing lean mass faster, and working harder to maintain the fitness standards that protect crew and the people they're pulling out of structure fires.
Mental performance
Mood dysregulation, depression, poor concentration, and reduced drive are all recognized symptoms of T deficiency. In a profession where decision-making under stress is a safety-critical function, this isn't abstract.
Cardiovascular health as a downstream signal
The occupational factors that suppress T — sleep disruption, shift work, chronic stress, chemical exposures — are independently associated with cardiovascular disease. Low T in a firefighter isn't just a hormone number. It's a warning light on the dashboard.
The Regulatory Record, Plainly Stated
The cardiovascular concern around TRT originated from a 2010 trial that was halted early due to adverse events. That study had significant methodological problems, but it set the tone for over a decade of warnings, cautious prescribing, and institutional guidance built around risk-first framing.
Then came TRAVERSE — the largest randomized controlled trial of TRT ever conducted. Over 5,200 men, nearly two years, rigorous design. The results: no increased risk of heart attack, stroke, or death compared to placebo. A 22.5% reduction in new-onset diabetes. Improvements in sexual function, libido, and mood.
The FDA reviewed those results and acted. February 28, 2025: the cardiovascular black box warning was removed from every testosterone product on the market. The agency that had required that warning for a decade looked at the evidence and reversed course.
At the December 2025 expert panel, Dr. Mohit Khera summarized where the evidence now stands:
"Today, we know that testosterone is not a carcinogen. It is not a cardiovascular risk factor. It's not mainly a lifestyle drug. What we do know is that testosterone plays a very important role across multiple organ systems throughout the body. In fact, testosterone deficiency negatively impacts health, reduces quality of life, and increases the risk for mortality."
The guidance you're receiving in department health materials was written before that statement was made, before that panel convened, and before the FDA acted. It reflects a risk calculus that the regulatory agency responsible for drug safety has formally revised.
The Risks That Remain — and Why They're Manageable
TRT is not without risks. That's not a disclaimer — it's the reason proper monitoring exists.
Erythrocytosis — increased red blood cell mass — is the most operationally relevant risk for active firefighters. Thicker blood combined with the heat stress and dehydration of fire suppression increases clotting risk. This is documented and real. Hemoglobin and hematocrit should be monitored regularly while on TRT, and your provider needs to know you're in active suppression duty.
Fertility suppression is concrete. TRT reliably suppresses sperm production. If fathering children is in your plans, that conversation happens with your provider before starting — there are alternative approaches that support testosterone production without the same impact on fertility.
Blood pressure is a newer, more nuanced concern. The same ABPM studies that informed the FDA's February 2025 action found statistically significant blood pressure increases with testosterone use. The FDA now requires product-specific blood pressure warnings. This doesn't override the cardiovascular safety data — it means BP monitoring joins the list of things a good provider tracks.
Early clotting risk is elevated in the first months of starting TRT, particularly in men with undiagnosed clotting disorders. A proper workup before starting is the appropriate response to this, not avoidance.
Managed vs. unmanaged
Managed risk is different from unmanaged risk. These aren't reasons to categorically avoid TRT. They're the checklist for doing it right.
What Legitimate TRT Care Looks Like
The warning to avoid "optimization clinics" and direct-to-consumer testosterone marketing exists for a reason. There are providers who over-prescribe, skip workups, and chase supranormal levels. That warning is valid.
But it's been used to make any proactive pursuit of testosterone treatment look suspect — and that's where it stops being protective and starts being a barrier. Here's what legitimate evaluation actually looks like:
Symptoms plus labs
A number without a clinical picture doesn't justify treatment. Symptoms without confirmed low levels don't either. Both together — that's a clinical problem with a clinical solution.
Monitoring after you start
Testosterone levels, PSA, hemoglobin, hematocrit, blood pressure at regular intervals. A provider who prescribes and disappears isn't doing the job.
Reversible causes identified first
If you're on opioids, sleeping under five hours, or carrying significant excess weight, those factors suppress T through mechanisms TRT doesn't fully override. Lifestyle changes and TRT aren't either/or — they work better together.
Why Your Department's Health Materials Are Behind
The IAFF information document still circulating in fire service health materials was published in October 2020. It predates TRAVERSE. It predates the FDA's February 2025 label changes. It predates the December 2025 expert panel. It was written under a regulatory framework that no longer exists.
The Seattle Fire Fighters HealthCare Trust post from October 2025 references TRAVERSE but was published eight months before the FDA acted on it — and it still leads with caution, still frames TRT as a last resort, still warns against "optimization."
Institutional health guidance has a lag. That's not bad faith — it's how institutions work. But your body doesn't wait for guidance documents to update.
Who the access gap hits hardest
The FDA expert panel said firefighters and first responders are among the populations most affected by the access gap. High physical demand, disrupted sleep, chronic stress, occupational exposures — the population most likely to have clinically meaningful T suppression is the population with the least time to navigate a four-month specialist waitlist.
The Bottom Line
The regulatory consensus on TRT cardiovascular risk has been formally reversed. The FDA removed the black box warning. An expert panel called TRT underutilized and called the current barriers a public health problem. The leading clinicians in urology and endocrinology are publicly stating that testosterone deficiency has been undertreated for a generation.
Low T in firefighters is not primarily an aging issue or a lifestyle issue. It's an occupational hazard with a documented clinical treatment that the largest safety trial ever run has cleared on the primary endpoint that kept it from broader use.
"You've spent your career operating in high-stakes environments with real consequences for bad decisions. Apply that same standard to your healthcare."
Know what proper evaluation looks like. Demand it. Don't let guidance written in 2020 determine what care you can access in 2025.
RespondWell connects first responders with independent licensed providers who can evaluate, prescribe, and monitor — without the referral chain, the four-month wait, or the formulary politics. If you qualify, you get care.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. All clinical decisions require evaluation by a licensed provider.